Adjuvant therapy for lung neuroendocrine neoplasms  

作　　者：Robert A Ramirez Katharine Thomas Aasems Jacob Karen Lin Yvette Bren-Mattison Aman Chauhan 

机构地区：[1]Department of Medicine-Division of Hematology/Oncology,Vanderbilt University Medical Center,Nashville,TN 37232,United States [2]Department of Hematology and Oncology,Louisiana State University Health Sciences Center,New Orleans,LA 70112,United States [3]Division of Medical Oncology,University of Kentucky,Lexington,KY 40536,United States [4]Department of Oncology,Brookwood Baptist Health,Birmingham,AL 35209,United States [5]Department of Surgery,Louisiana State University Health Sciences Center,New Orleans,LA 70112,United States [6]New Orleans Louisiana Neuroendocrine Tumor Specialists(NOLANETS),Ochsner Medical Center,Kenner,LA 70065,United States

出　　处：《World Journal of Clinical Oncology》2021年第8期664-674,共11页世界临床肿瘤学杂志（英文版）

摘　　要：Pulmonary neuroendocrine neoplasms(NENs)represent a minority of lung cancers and vary from slower growing pulmonary carcinoid(PC)tumors to aggressive small cell lung cancer(SCLC).While SCLC can account for up to 15%of lung cancer,PCs are uncommon and represent about 2%of lung cancers.Surgical resection is the standard of care for early-stage PCs and should also be considered in early stage large cell neuroendocrine carcinoma(LCNEC)and SCLC.Adjuvant treatment is generally accepted for aggressive LCNEC and SCLC,however,less well established for PCs.Guidelines admit a lack of trials to support a high-level recommendation for adjuvant therapy.This manuscript will discuss the role for adjuvant therapy in NENs and review the available literature.

关 键 词：NEUROENDOCRINE Adjuvant therapy LUNG Pulmonary carcinoid Small cell lung cancer 

分 类 号：R734.2[医药卫生—肿瘤]